Authors:
SMITHSORENSEN B
KAERN J
HOLM R
DORUM A
TROPE C
BORRESENDALE AL
Citation: B. Smithsorensen et al., THERAPY EFFECT OF EITHER PACLITAXEL OR CYCLOPHOSPHAMIDE COMBINATION TREATMENT IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER AND RELATION TO TP53 GENE STATUS, British Journal of Cancer, 78(3), 1998, pp. 375-381
Authors:
AAS T
BORRESEN AL
GEISLER S
SMITHSORENSEN B
JOHNSEN H
VARHAUG JE
AKSLEN LA
LONNING PE
Citation: T. Aas et al., SPECIFIC P53 MUTATIONS ARE ASSOCIATED WITH DE-NOVO RESISTANCE TO DOXORUBICIN IN BREAST-CANCER PATIENTS, Nature medicine, 2(7), 1996, pp. 811-814
Authors:
SMITHSORENSEN B
HIJMANS EM
BEIJERSBERGEN RL
BERNARDS R
Citation: B. Smithsorensen et al., FUNCTIONAL-ANALYSIS OF BURKITTS-LYMPHOMA MUTANT C-MYC PROTEINS, The Journal of biological chemistry, 271(10), 1996, pp. 5513-5518
Authors:
KRAWCZAK M
SMITHSORENSEN B
SCHMIDTKE J
KAKKAR VV
COOPER DN
HOVIG E
Citation: M. Krawczak et al., SOMATIC SPECTRUM OF CANCER-ASSOCIATED SINGLE BASEPAIR SUBSTITUTIONS IN THE TP53 GENE IS DETERMINED MAINLY BY ENDOGENOUS MECHANISMS OF MUTATION AND BY SELECTION, Human mutation, 5(1), 1995, pp. 48-57
Authors:
MCINTYRE JF
SMITHSORENSEN B
FRIEND SH
KASSELL J
BORRESEN AL
YAN YX
RUSSO C
SATO J
BARBIER N
MISER J
MALKIN D
GEBHARDT MC
Citation: Jf. Mcintyre et al., GERMLINE MUTATIONS OF THE P53 TUMOR-SUPPRESSOR GENE IN CHILDREN WITH OSTEOSARCOMA, Journal of clinical oncology, 12(5), 1994, pp. 925-930
Authors:
HOLLSTEIN M
RICE K
GREENBLATT MS
SOUSSI T
FUCHS R
SORLIE T
HOVIG E
SMITHSORENSEN B
MONTESANO R
HARRIS CC
Citation: M. Hollstein et al., DATABASE OF P53 GENE SOMATIC MUTATIONS IN HUMAN TUMORS AND CELL-LINES, Nucleic acids research, 22(17), 1994, pp. 3551-3555
Authors:
SMITHSORENSEN B
GEBHARDT MC
KLOEN P
MCINTYRE J
AGUILAR F
CERUTTI P
BORRESEN AL
Citation: B. Smithsorensen et al., SCREENING FOR TP53 MUTATIONS IN OSTEOSARCOMAS USING CONSTANT DENATURANT GEL-ELECTROPHORESIS (CDGE), Human mutation, 2(4), 1993, pp. 274-285